title: LPS from Escherichia coli protects against indomethacin-induced gastropathy in rats--role of ATP-sensitive potassium channels.
abstract: The effect of lipopolysaccharide (LPS) in gastric protection has not been elucidated, but ATP-sensitive potassium (K(ATP)) channels are known to be involved in gastric defense. We evaluated the effect of LPS administration on indomethacin-induced gastropathy, and the role of K(ATP) channels in this event. Rats received intravenous (i.v.) LPS administration. After 1/2, 6, 24 or 48 h, indomethacin was injected. 3H later, gastric damage and myeloperoxidase activity were determined. Another group received LPS and 5 h later, glibenclamide, diazoxide or glibenclamide plus diazoxide. After 1 h, the rats received indomethacin and 3 h later, gastric damage and myeloperoxidase activity were evaluated. LPS reduced dose dependently gastric damage and myeloperoxidase activity induced by indomethacin. Glibenclamide reversed this LPS effect on indomethacin-induced gastropathy. Glibenclamide plus diazoxide administration did not change this LPS effect. Thus LPS has a protective effect against indomethacin-induced gastropathy, probably through activation of K(ATP) channels.
authors.affiliation: Department of Physiology and Pharmacology, Federal University of Ceará-Brazil, Brazil.
authors.forename: Antoniella S
authors.initials: AS
authors.lastname: Gomes
authors.forename: Lívia M F
authors.initials: LM
authors.lastname: Lima
authors.forename: Camila L
authors.initials: CL
authors.lastname: Santos
authors.forename: Fernando Q
authors.initials: FQ
authors.lastname: Cunha
authors.forename: Ronaldo A
authors.initials: RA
authors.lastname: Ribeiro
authors.forename: Marcellus H L P
authors.initials: MH
authors.lastname: Souza
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000633:toxicity; D001786:Blood Glucose / Q000378:metabolism; D003981:Diazoxide / Q000008:administration & dosage / Q000494:pharmacology; D004926:Escherichia coli / Q000737:chemistry; D005905:Glyburide / Q000008:administration & dosage / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology; D007213:Indomethacin / Q000008:administration & dosage / Q000633:toxicity*; D007275:Injections, Intravenous; D007958:Leukocyte Count; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009195:Peroxidase / Q000378:metabolism; D024661:Potassium Channels, Inwardly Rectifying / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D020011:Protective Agents / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013272:Stomach Diseases / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D008070:Lipopolysaccharides; D024661:Potassium Channels, Inwardly Rectifying; D020011:Protective Agents; C440499:lipopolysaccharide, Escherichia coli O111 B4; D009195:Peroxidase; D003981:Diazoxide; D005905:Glyburide; D007213:Indomethacin